# A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders

> **NCT06392074** · PHASE1 · COMPLETED · sponsor: **mAbxience Research S.L.** · enrollment: 141 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MB04
- **DRUG:** US License Enbrel
- **DRUG:** EU Source Enbrel

## Key facts

- **NCT ID:** NCT06392074
- **Lead sponsor:** mAbxience Research S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-07
- **Primary completion:** 2025-05-12
- **Final completion:** 2025-05-12
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06392074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06392074, "A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06392074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*